Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vyteris has reported that osteoarthritis pain drug LidoSite provided better pain relief to the majority of patients then usual topical analgesics in a phase IV trial.
Subscribe to our email newsletter
The US-based company said that more than 73% of patients receiving injections of hyaluronic acid during treatment for osteoarthritis experienced better pain relief to standard treatment. The study, involving six study sites and 14 physicians, followed 63 patients over the course of two routine injections of hyaluronic acid for the treatment of osteoarthritis.
During the first treatment, patients either received no local anesthesia or an alternate local anesthesia prior to cannulation or needle puncture. During the second treatment, patients received the LidoSite system, comprised of the LidoSite Patch and the LidoSite Controller. In the study, more than 73% preferred LidoSite to the treatment used during their first visit.
“This initial study demonstrates the acceptability among patients and rheumatologists for using LidoSite as an effective treatment regime for needle pain for the multiple injections arthritis requires, as well as its potential availability in the doctor’s office setting,” said Timothy McIntyre, president and CEO of Vyteris.